Business Context and Reporting Period
Company: AngioDynamics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 7, 2016
Reporting Period: Fiscal third quarter ended February 29, 2016.
Context: The filing serves to announce the issuance of a press release detailing financial results for the specified quarter. The detailed financial data is contained in Exhibit 99.1 (Press Release) and is not explicitly restated within the body of this 8-K text.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the attached press release (Exhibit 99.1) but are not present in the filing text itself.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms that results for the fiscal third quarter ended February 29, 2016, have been announced.
Guidance, Outlook, and Risks
Forward-Looking Statements: The document contains forward-looking statements regarding expected future financial position, results of operations, cash flows, business strategy, and growth opportunities. These are subject to risks and uncertainties and are not guarantees of future performance.
Key Risks and Uncertainties:
- Ability to develop existing and new products.
- Technological advances and patents attained by competitors.
- Intellectual property infringement claims (both against and by the Company).
- Competition from entities with substantially greater resources.
- Future actions by the FDA or other regulatory agencies.
- Domestic and foreign health care reforms and government regulations.
- Results of pending or future clinical trials.
- Overall economic conditions and foreign currency exchange rate fluctuations.
- Effects of product recalls and product liability claims.
- Challenges with third-party distributors, joint venture partners, or collaborators.
- Changes in key personnel and ability to execute strategic initiatives.
- Effects of pricing from group purchasing organizations.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, earnings, and cash flow figures for the quarter ended February 29, 2016.
- Verify the Company's guidance and outlook statements provided in the press release against the risks outlined in this filing.
- Check recent Form 10-K and Form 10-Q filings for detailed risk factors and historical financial trends.
- Monitor regulatory updates from the FDA regarding the Company's product pipeline.
- Assess the impact of foreign currency exchange rates on international operations.